<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064025</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0211</org_study_id>
    <secondary_id>NCI-2012-02539</secondary_id>
    <secondary_id>CDR0000306440</secondary_id>
    <secondary_id>GOG-0211</secondary_id>
    <secondary_id>GOG-0211</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00064025</nct_id>
  </id_info>
  <brief_title>Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus</brief_title>
  <official_title>A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well medroxyprogesterone works in treating patients with
      endometrioid adenocarcinoma (cancer) of the uterine corpus (the body of the uterus, not
      including the cervix). Hormone therapy using medroxyprogesterone may be effective in treating
      endometrioid cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Compare the efficacy of medroxyprogesterone, in terms of induction of histologic response,
      in patients with progesterone receptor-positive vs progesterone receptor-negative
      endometrioid adenocarcinoma of the uterine corpus.

      II. Determine the early and late changes in gene expression at 72 hours and 21 days in
      patients treated with this drug.

      III. Examine the mechanisms surrounding the dynamic changes in endometrial tumor cells by
      determining possible correlations among histologic response, steroid receptor status,
      immunohistochemical measures of growth and apoptosis, and gene expression profiles in
      patients treated with this drug.

      OUTLINE: This is a pilot, multicenter study.

      Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before
      surgical hysterectomy.

      A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72
      hours after medroxyprogesterone therapy, and during surgery for gene expression arrays.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative</measure>
    <time_frame>During the hysterectomy, which is 21-24 days after administration of depo-provera</time_frame>
    <description>To determine the presence of a histologic response, the slide from the initial sample was compared to the slide from the matching hysterectomy specimen. A complete histologic response was defined as the absence of identifiable adenocarcinoma in the hysterectomy specimen section. A partial histologic response was subjectively defined in advance of the study based on criteria slightly modified from Wheeler et al. (Am J Surg Pathol 2007;31:988-98) as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample. A complete or partial histologic response was considered a histologic response in the analysis of data.
PR Positivity is based on aggregate score &gt;0.2 (vs. &lt;=0.2). Aggregate score based on product of staining intensity and area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Pre- to Post-treatment in Estrogren Receptor (ER) Expression</measure>
    <time_frame>During the hysterectomy, which is 21-24 days after administration of depo-provera</time_frame>
    <description>Expression is based on an aggregate score based on immunohistochemistry. Staining intensity was scored 1, 2, or 3; and staining area was scored as a percentage (0-100%). The aggregate score is the product of staining intensity and area and ranges from 0 to 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre- to Post-treatment in Progestrogren Receptor (PR) Expression</measure>
    <time_frame>During the hysterectomy , which is 21-24 days after administration of depo-provera</time_frame>
    <description>Expression is based on an aggregate score based on immunohistochemistry. Staining intensity was scored 1, 2, or 3; and staining area was scored as a percentage (0-100%). The aggregate score is the product of staining intensity and area and ranges from 0 to 3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Endometrial Adenocarcinoma</condition>
  <condition>Endometrial Adenosquamous Carcinoma</condition>
  <condition>Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation</condition>
  <condition>Recurrent Uterine Corpus Carcinoma</condition>
  <condition>Stage I Uterine Corpus Cancer</condition>
  <condition>Stage II Uterine Corpus Cancer</condition>
  <condition>Stage III Uterine Corpus Cancer</condition>
  <condition>Stage IV Uterine Corpus Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (medroxyprogesterone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive medroxyprogesterone intramuscularly once approximately 3 weeks before surgical hysterectomy.
A subset of 15 patients has tissue collected by pipelle biopsy or curettage at baseline, 72 hours after medroxyprogesterone therapy, and during surgery for gene expression arrays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (medroxyprogesterone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Treatment (medroxyprogesterone)</arm_group_label>
    <other_name>Curretab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgical hysterectomy</description>
    <arm_group_label>Treatment (medroxyprogesterone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary endometrioid adenocarcinoma of the uterine corpus

               -  All histologic grades and stages eligible

               -  Diagnosis by endometrial curettage or biopsy within the past 8 weeks

                    -  Must have the initial tissue block or 16 unstained sections of 5 micron
                       thickness available

          -  Performance status - GOG 0-3

          -  No history of thrombophlebitis or thromboembolic disorders

          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

          -  No prior therapeutic progesterone or anti-estrogen therapy within 3 months before
             diagnosis

          -  No concurrent aminoglutethimide

          -  No prior cancer treatment that would preclude study therapy

          -  No concurrent bosentan

          -  No concurrent rifampin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Zaino</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <results_first_submitted>January 31, 2014</results_first_submitted>
  <results_first_submitted_qc>July 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Endometrioid</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was activated on 4/12/2004 and closed to accrual on 9/2/2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Depo-Provera</title>
          <description>Depo-Provera (Medroxyprogesterone Acetate) 400 mg IM, Given Once, 21-24 Days Prior to Hysterectomy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inevaluable</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Depo-Provera</title>
          <description>Depo-Provera (Medroxyprogesterone Acetate) 400 mg IM, Given Once, 21-24 Days Prior to Hysterectomy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative</title>
        <description>To determine the presence of a histologic response, the slide from the initial sample was compared to the slide from the matching hysterectomy specimen. A complete histologic response was defined as the absence of identifiable adenocarcinoma in the hysterectomy specimen section. A partial histologic response was subjectively defined in advance of the study based on criteria slightly modified from Wheeler et al. (Am J Surg Pathol 2007;31:988-98) as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample. A complete or partial histologic response was considered a histologic response in the analysis of data.
PR Positivity is based on aggregate score &gt;0.2 (vs. &lt;=0.2). Aggregate score based on product of staining intensity and area.</description>
        <time_frame>During the hysterectomy, which is 21-24 days after administration of depo-provera</time_frame>
        <population>Eligible and Evaluable Patients (patients who had both an intake biopsy and hysterectomy and had histologic response data)</population>
        <group_list>
          <group group_id="O1">
            <title>PR Negative (&lt;=0.2)</title>
          </group>
          <group group_id="O2">
            <title>PR Positive (&gt;0.2)</title>
          </group>
        </group_list>
        <measure>
          <title>Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor Negative</title>
          <description>To determine the presence of a histologic response, the slide from the initial sample was compared to the slide from the matching hysterectomy specimen. A complete histologic response was defined as the absence of identifiable adenocarcinoma in the hysterectomy specimen section. A partial histologic response was subjectively defined in advance of the study based on criteria slightly modified from Wheeler et al. (Am J Surg Pathol 2007;31:988-98) as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample. A complete or partial histologic response was considered a histologic response in the analysis of data.
PR Positivity is based on aggregate score &gt;0.2 (vs. &lt;=0.2). Aggregate score based on product of staining intensity and area.</description>
          <population>Eligible and Evaluable Patients (patients who had both an intake biopsy and hysterectomy and had histologic response data)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.701</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre- to Post-treatment in Estrogren Receptor (ER) Expression</title>
        <description>Expression is based on an aggregate score based on immunohistochemistry. Staining intensity was scored 1, 2, or 3; and staining area was scored as a percentage (0-100%). The aggregate score is the product of staining intensity and area and ranges from 0 to 3.</description>
        <time_frame>During the hysterectomy, which is 21-24 days after administration of depo-provera</time_frame>
        <population>Eligible and Evaluable Patients (patients who had both an intake biopsy and hysterectomy)</population>
        <group_list>
          <group group_id="O1">
            <title>Depo-Provera</title>
            <description>Depo-Provera (Medroxyprogesterone Acetate) 400 mg IM, Given Once, 21-24 Days Prior to Hysterectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre- to Post-treatment in Estrogren Receptor (ER) Expression</title>
          <description>Expression is based on an aggregate score based on immunohistochemistry. Staining intensity was scored 1, 2, or 3; and staining area was scored as a percentage (0-100%). The aggregate score is the product of staining intensity and area and ranges from 0 to 3.</description>
          <population>Eligible and Evaluable Patients (patients who had both an intake biopsy and hysterectomy)</population>
          <units>Aggregate Score from Immunohistochemistr</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre- to Post-treatment in Progestrogren Receptor (PR) Expression</title>
        <description>Expression is based on an aggregate score based on immunohistochemistry. Staining intensity was scored 1, 2, or 3; and staining area was scored as a percentage (0-100%). The aggregate score is the product of staining intensity and area and ranges from 0 to 3.</description>
        <time_frame>During the hysterectomy , which is 21-24 days after administration of depo-provera</time_frame>
        <population>Eligible and Evaluable Patients (patients who had both an intake biopsy and hysterectomy)</population>
        <group_list>
          <group group_id="O1">
            <title>Depo-Provera</title>
            <description>Depo-Provera (Medroxyprogesterone Acetate) 400 mg IM, Given Once, 21-24 Days Prior to Hysterectomy</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre- to Post-treatment in Progestrogren Receptor (PR) Expression</title>
          <description>Expression is based on an aggregate score based on immunohistochemistry. Staining intensity was scored 1, 2, or 3; and staining area was scored as a percentage (0-100%). The aggregate score is the product of staining intensity and area and ranges from 0 to 3.</description>
          <population>Eligible and Evaluable Patients (patients who had both an intake biopsy and hysterectomy)</population>
          <units>Aggregate Score from Immunohistochemistr</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Toxicity was assessed from the time of study drug administration to the time of the hysterectomy, which occurred 21-24 days after study drug administration.</time_frame>
      <desc>This study had no Serious Adverse Events (SAEs).</desc>
      <group_list>
        <group group_id="E1">
          <title>Depo-Provera</title>
          <description>Depo-Provera (Medroxyprogesterone Acetate) 400 mg IM, Given Once, 21-24 Days Prior to Hysterectomy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Lymphatics - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Edema: Limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain: Breast</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain: Uterus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain: Head/Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain: Extremity-Limb</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain: Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pain: Abdominal Pain Nos</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/Immunology - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Inf Unknown Anc: Skin (Cellulitis)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic/Laboratory - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Alteration - Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Mood Alteration - Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Irregular Menses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Gu - Vagina</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessalyn Reboy</name_or_title>
      <organization>Gynecologic Oncology Group Statistical and Data Center</organization>
      <phone>716-845-7738</phone>
      <email>reboyj@norgoncology.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

